Axogen Inc vs Wells Fargo & Co — how do they compare? Axogen Inc trades at $38.66 (market cap $2.06B), while Wells Fargo & Co trades at $86.93 (market cap $258.30B). The key difference: Wells Fargo & Co is far larger — about 125.4× Axogen Inc's market cap, and Wells Fargo & Co pays a 2.11% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | WFC | |
|---|---|---|
Market Cap | $2.06B | $258.30B |
Sector | Technology | Financials |
52-Week High | $46.19 | $96.40 |
52-Week Low | $11.28 | $73.42 |
Enterprise Value | $1.98B | — |
Dividend Yield | — | 2.11% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
Wells Fargo (WFC) trades at $87.70, up 0.67% with a bullish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $2.00 versus $1.73 expected, driven by net interest income and fee growth. Revenue trends upward from $83.7B in 2025 to projected $85.0B in 2026, while net income margin remains robust at 25.5%. Recent news highlights the bank's $1B+ technology investment in AI tools for wealth management and a healthy investment banking pipeline.
The outlook is positive with a consensus price target of $99.10 offering 13% upside. Key opportunities include continued earnings momentum and efficiency gains from tech investments. Risks involve expense pressures, macroeconomic sensitivity, and competitive banking sector dynamics. Analyst sentiment is mixed with 45% buy ratings but near-term execution on guidance will be critical for sustained outperformance.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →